TY - JOUR
T1 - Characteristics and outcomes of granulomatosis with polyangiitis (Wegener) and microscopic polyangiitis requiring renal replacement therapy
T2 - Results from the european renal association-european dialysis and transplant association registry
AU - Hruskova, Zdenka
AU - Stel, Vianda S.
AU - Jayne, David
AU - Aasarød, Knut
AU - De Meester, Johan
AU - Ekstrand, Agneta
AU - Eller, Kathrin
AU - Heaf, James G.
AU - Hoitsma, Andries
AU - Martos Jimenéz, Carmen
AU - Ravani, Pietro
AU - Wanner, Christoph
AU - Tesar, Vladimir
AU - Jager, Kitty J.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Background This study describes the incidence and outcomes of European patients requiring renal replacement therapy (RRT) for kidney failure due to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Study Design Cohort study. Setting & Participants 12 renal registries providing individual RRT patient data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry in 1993-2012 participated. Predictor Cause of primary kidney disease: AAV (ie, granulomatosis with polyangiitis [Wegener] and microscopic polyangiitis) versus 3 separate matched control groups without AAV: (1) primary glomerulonephritis, (2) diabetes mellitus, and (3) disease other than diabetes mellitus as the cause of primary kidney disease, including glomerulonephritis (termed "nondiabetes"). Outcomes Incidence, causes of death, and survival. Measurements ERA-EDTA primary renal disease codes. Results 2,511 patients with AAV (1,755, granulomatosis with polyangiitis; 756, microscopic polyangiitis) were identified, representing an incidence of 1.05 per million population (pmp) for granulomatosis with polyangiitis (predominating in Northern Europe) and 0.45 pmp for microscopic polyangiitis (prevailing in Southern Europe). Kidney transplantation was performed in 558 (22.2%) patients with vasculitis. The 10-year probability for survival on RRT after day 91 was 32.5% (95% CI, 29.9%-35.1%) in patients with vasculitis. Survival on RRT after day 91 did not differ between AAV and matched nondiabetes patients. Patient and transplant survival after kidney transplantation, adjusted for time period and country, was better in AAV than in matched nondiabetes patients (HRs of 0.81 [95% CI, 0.67-0.99] and 0.82 [95% CI, 0.69-0.96], respectively). Limitations No data for extrarenal manifestations, treatment, and relapses. Conclusions Geographical differences in the incidence of RRT for kidney failure due to granulomatosis with polyangiitis and microscopic polyangiitis copied their distribution in the general population. Overall survival on RRT after day 91 for patients with AAV was similar to that for patients with nondiabetes diagnoses. Our results suggest that patients with AAV are suitable candidates for kidney transplantation with favorable survival outcomes.
AB - Background This study describes the incidence and outcomes of European patients requiring renal replacement therapy (RRT) for kidney failure due to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Study Design Cohort study. Setting & Participants 12 renal registries providing individual RRT patient data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry in 1993-2012 participated. Predictor Cause of primary kidney disease: AAV (ie, granulomatosis with polyangiitis [Wegener] and microscopic polyangiitis) versus 3 separate matched control groups without AAV: (1) primary glomerulonephritis, (2) diabetes mellitus, and (3) disease other than diabetes mellitus as the cause of primary kidney disease, including glomerulonephritis (termed "nondiabetes"). Outcomes Incidence, causes of death, and survival. Measurements ERA-EDTA primary renal disease codes. Results 2,511 patients with AAV (1,755, granulomatosis with polyangiitis; 756, microscopic polyangiitis) were identified, representing an incidence of 1.05 per million population (pmp) for granulomatosis with polyangiitis (predominating in Northern Europe) and 0.45 pmp for microscopic polyangiitis (prevailing in Southern Europe). Kidney transplantation was performed in 558 (22.2%) patients with vasculitis. The 10-year probability for survival on RRT after day 91 was 32.5% (95% CI, 29.9%-35.1%) in patients with vasculitis. Survival on RRT after day 91 did not differ between AAV and matched nondiabetes patients. Patient and transplant survival after kidney transplantation, adjusted for time period and country, was better in AAV than in matched nondiabetes patients (HRs of 0.81 [95% CI, 0.67-0.99] and 0.82 [95% CI, 0.69-0.96], respectively). Limitations No data for extrarenal manifestations, treatment, and relapses. Conclusions Geographical differences in the incidence of RRT for kidney failure due to granulomatosis with polyangiitis and microscopic polyangiitis copied their distribution in the general population. Overall survival on RRT after day 91 for patients with AAV was similar to that for patients with nondiabetes diagnoses. Our results suggest that patients with AAV are suitable candidates for kidney transplantation with favorable survival outcomes.
KW - ANCA-associated vasculitis (AAV)
KW - Antineutrophil cytoplasmic antibody (ANCA)
KW - dialysis
KW - end-stage renal disease (ESRD)
KW - granulomatosis with polyangiitis (GPA) [Wegener]
KW - kidney transplantation
KW - microscopic polyangiitis (MPA)
KW - outcomes
KW - renal replacement therapy (RRT)
UR - http://www.scopus.com/inward/record.url?scp=84942292595&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2015.03.025
DO - 10.1053/j.ajkd.2015.03.025
M3 - Article
C2 - 25975963
AN - SCOPUS:84942292595
SN - 0272-6386
VL - 66
SP - 613
EP - 620
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 4
ER -